Adamis Pharmaceuticals Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ADMP Nasdaq 2834 http://www.adamispharmaceuticals.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q4 2022 Earnings Call Transcript - Mar 20th, 2023 2:33 am
Q4 2022 Adamis Pharmaceuticals Corp Earnings Call - Mar 17th, 2023 12:40 pm
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update - Mar 16th, 2023 8:24 pm
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update - Mar 14th, 2023 8:01 pm
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering - Mar 14th, 2023 12:30 pm
Opioid Focused Adamis Pharma Agrees To Merge With Privately Held DMK Pharmaceuticals - Feb 28th, 2023 1:22 pm
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger - Feb 27th, 2023 9:05 pm
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements - Feb 22nd, 2023 9:01 pm
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q3 2022 Earnings Call Transcript - Dec 29th, 2022 11:02 am
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 9:10 pm
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update - Nov 7th, 2022 9:05 pm
Adamis Pharmaceuticals Seeks Strategic Options, Including Sale - Oct 4th, 2022 10:27 am
Adamis Announces Review of Strategic Alternatives - Oct 3rd, 2022 8:30 pm
Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy - Sep 21st, 2022 1:58 pm
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects - Sep 21st, 2022 11:30 am
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects - Sep 12th, 2022 8:05 pm
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders - Aug 12th, 2022 9:00 pm
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Aug 10th, 2022 8:02 pm
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update - Aug 8th, 2022 11:30 am
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting - Jul 29th, 2022 12:00 pm